niacinamide has been researched along with Kidney Failure, Chronic in 25 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In our patients, nicotinamide effectively decreased phosphorus, increased high-density lipoprotein, and caused thrombocytopenia." | 9.15 | Oral nicotinamide reduces serum phosphorus, increases HDL, and induces thrombocytopenia in hemodialysis patients: a double-blind randomized clinical trial. ( Abbaspour, MR; Belladi Musavi, SS; Ghorbani, A; Hayati, F; Lashkarara, GR; Shahbazian, H; Zafar Mohtashami, A, 2011) |
| "Secondary hyperparathyroidism has a significant impact on morbidity and mortality due to skeletal and extraskeletal manifestations." | 6.44 | Pharmacological control of secondary hyperparathyroidism in chronic hemodialysis patients: cinacalcet is coming to Japan. ( Iseki, K, 2008) |
| "In our patients, nicotinamide effectively decreased phosphorus, increased high-density lipoprotein, and caused thrombocytopenia." | 5.15 | Oral nicotinamide reduces serum phosphorus, increases HDL, and induces thrombocytopenia in hemodialysis patients: a double-blind randomized clinical trial. ( Abbaspour, MR; Belladi Musavi, SS; Ghorbani, A; Hayati, F; Lashkarara, GR; Shahbazian, H; Zafar Mohtashami, A, 2011) |
| " The major adverse events associated with the NAM therapy were diarrhea, flushing and nausea." | 2.82 | Efficacy and safety of nicotinamide in the management of hyperphosphatemia in pediatric patients on regular hemodialysis. ( El Borolossy, R; El Hakim, I; El Wakeel, LM; Sabri, N, 2016) |
| "Secondary hyperparathyroidism has a significant impact on morbidity and mortality due to skeletal and extraskeletal manifestations." | 2.44 | Pharmacological control of secondary hyperparathyroidism in chronic hemodialysis patients: cinacalcet is coming to Japan. ( Iseki, K, 2008) |
| "Treatment with sorafenib of patients with metastatic renal cell carcinoma undergoing hemodialysis appears to be feasible, but we express some concern about the higher incidence of serious adverse events even with the reduced dose." | 1.37 | Clinical results and pharmacokinetics of sorafenib in chronic hemodialysis patients with metastatic renal cell carcinoma in a single center. ( Hashimoto, Y; Iizuka, J; Ishimori, I; Kennoki, T; Kimata, N; Kobayashi, H; Kondo, T; Murakami, J; Nakazawa, H; Takagi, T; Tanabe, K; Yoshida, K, 2011) |
| "Sorafenib seems to be a safe treatment option for patients with ESRD and mRCC, but further studies are required." | 1.35 | Successful sorafenib treatment for metastatic renal cell carcinoma in a case with chronic renal failure. ( Hakenberg, OW; Klebingat, KJ; Protzel, C; Ruppin, S, 2009) |
| "However, in chronic renal failure (CRF), serum 1,25(OH)(2)D and Pi levels are often abnormal." | 1.33 | Nicotinamide prevents the development of hyperphosphataemia by suppressing intestinal sodium-dependent phosphate transporter in rats with adenine-induced renal failure. ( Eto, N; Miyata, Y; Ohno, H; Yamashita, T, 2005) |
| "Our hypothesis was that chronic renal failure would lead to elevation of 2PY and potentially to inhibition of PARP and related physiological mechanisms." | 1.31 | Accumulation of plasma N-methyl-2-pyridone-5-carboxamide in patients with chronic renal failure. ( Leaver, N; Rutkowski, B; Simmonds, HA; Slominska, EM; Smolenski, RT; Swierczynski, J; Szolkiewicz, M, 2002) |
| " The dose-response curve is similar to that of a known competitive inhibitor, hippuric acid, and the average inhibitory activity of uremic extract as derived from these curves was 3." | 1.26 | Suppression of tubular anion transport by an inhibitor of serum protein binding in uremia. ( Depner, TA, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (8.00) | 18.7374 |
| 1990's | 2 (8.00) | 18.2507 |
| 2000's | 10 (40.00) | 29.6817 |
| 2010's | 9 (36.00) | 24.3611 |
| 2020's | 2 (8.00) | 2.80 |
| Authors | Studies |
|---|---|
| Marafi, F | 1 |
| Sasikumar, A | 1 |
| Aldaas, M | 1 |
| Esmail, A | 1 |
| Lenglet, A | 2 |
| Rahali, MA | 1 |
| Sauvage, FL | 1 |
| Liabeuf, S | 2 |
| Choukroun, G | 1 |
| Essig, M | 1 |
| El Balkhi, S | 1 |
| Massy, ZA | 2 |
| Snaidr, VA | 1 |
| Damian, DL | 1 |
| Halliday, GM | 1 |
| Rennick, A | 1 |
| Kalakeche, R | 1 |
| Seel, L | 1 |
| Shepler, B | 1 |
| Guffroy, P | 1 |
| Fournier, A | 1 |
| Brazier, M | 1 |
| Shetty, AV | 1 |
| Matrana, MR | 1 |
| Atkinson, BJ | 1 |
| Flaherty, AL | 1 |
| Jonasch, E | 1 |
| Tannir, NM | 1 |
| El Borolossy, R | 1 |
| El Wakeel, LM | 1 |
| El Hakim, I | 1 |
| Sabri, N | 1 |
| Ruppin, S | 1 |
| Protzel, C | 1 |
| Klebingat, KJ | 1 |
| Hakenberg, OW | 1 |
| Shahbazian, H | 1 |
| Zafar Mohtashami, A | 1 |
| Ghorbani, A | 1 |
| Abbaspour, MR | 1 |
| Belladi Musavi, SS | 1 |
| Hayati, F | 1 |
| Lashkarara, GR | 1 |
| Kennoki, T | 1 |
| Kondo, T | 1 |
| Kimata, N | 1 |
| Murakami, J | 1 |
| Ishimori, I | 1 |
| Nakazawa, H | 1 |
| Hashimoto, Y | 1 |
| Kobayashi, H | 1 |
| Iizuka, J | 1 |
| Takagi, T | 1 |
| Yoshida, K | 1 |
| Tanabe, K | 1 |
| Bobin-Dubigeon, C | 1 |
| Heurgue-Berlot, A | 1 |
| Bouché, O | 1 |
| Amiand, MB | 1 |
| Le Guellec, C | 1 |
| Bard, JM | 1 |
| Masini, C | 1 |
| Sabbatini, R | 1 |
| Porta, C | 1 |
| Procopio, G | 1 |
| Di Lorenzo, G | 1 |
| Onofri, A | 1 |
| Buti, S | 1 |
| Iacovelli, R | 1 |
| Invernizzi, R | 1 |
| Moscetti, L | 1 |
| Aste, MG | 1 |
| Pagano, M | 1 |
| Grosso, F | 1 |
| Lucia Manenti, A | 1 |
| Ortega, C | 1 |
| Cosmai, L | 1 |
| Del Giovane, C | 1 |
| Conte, PF | 1 |
| Takahashi, Y | 1 |
| Tanaka, A | 1 |
| Nakamura, T | 1 |
| Fukuwatari, T | 1 |
| Shibata, K | 1 |
| Shimada, N | 1 |
| Ebihara, I | 1 |
| Koide, H | 1 |
| Eto, N | 1 |
| Miyata, Y | 1 |
| Ohno, H | 1 |
| Yamashita, T | 1 |
| Bover, J | 1 |
| Ortiz-Herbener, F | 1 |
| Ballarín, J | 1 |
| Andrés, E | 1 |
| Barceló, P | 1 |
| Rottembourg, JB | 1 |
| Launay-Vacher, V | 1 |
| Massard, J | 1 |
| Slominska, EM | 3 |
| Kowalik, K | 1 |
| Smolenski, RT | 4 |
| Szolkiewicz, M | 2 |
| Rutkowski, P | 2 |
| Rutkowski, B | 3 |
| Swierczynski, J | 3 |
| Carrey, EA | 1 |
| Foks, H | 1 |
| Orlewska, C | 1 |
| Wieczerzak, E | 1 |
| Sowinski, P | 1 |
| Yacoub, MH | 1 |
| Marinaki, AM | 1 |
| Simmonds, HA | 2 |
| Słominska, EM | 1 |
| Szołkiewicz, M | 1 |
| Aleksandrowicz, E | 1 |
| Wołyniec, W | 1 |
| Renke, M | 1 |
| Wisterowicz, K | 1 |
| Iseki, K | 1 |
| Depner, TA | 1 |
| Leaver, N | 1 |
| Nasseri, K | 1 |
| Daley-Yates, PT | 2 |
| Maiza, A | 1 |
| McVicar, M | 1 |
| Gauthier, B | 1 |
| Goodman, CT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Efficacy and Safety of Niacin on Hyperphosphatemia in End Stage Renal Disease Patients Undergoing Haemodialysis[NCT03163576] | Phase 4 | 150 participants (Anticipated) | Interventional | 2017-06-30 | Not yet recruiting | ||
| Comparison of Nicotinamide and Sevelamer Hydrochloride on Phosphatemia Control on Chronic Hemodialysed Patients[NCT01011699] | Phase 3 | 176 participants (Actual) | Interventional | 2010-01-31 | Terminated (stopped due to Financial problem) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for niacinamide and Kidney Failure, Chronic
| Article | Year |
|---|---|
Nicotinamide for photoprotection and skin cancer chemoprevention: A review of efficacy and safety.
Topics: Adenosine Triphosphate; Animals; Anti-Inflammatory Agents; Chemoprevention; Dermatology; DNA Damage; | 2019 |
Nicotinic acid and nicotinamide: a review of their use for hyperphosphatemia in dialysis patients.
Topics: Animals; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Niacin; Niacinamide; Peritoneal Dialysi | 2013 |
Use of nicotinamide to treat hyperphosphatemia in dialysis patients.
Topics: Humans; Hyperphosphatemia; Kidney Failure, Chronic; Niacinamide; Phosphates; Renal Dialysis; Sodium- | 2013 |
[New therapy strategies in secondary hyperparathyroidism on dialysis (I): new concepts, new treatments].
Topics: Algorithms; Bile Acids and Salts; Calcium; Cardiovascular Diseases; Disease Progression; Drug Therap | 2005 |
Pharmacological control of secondary hyperparathyroidism in chronic hemodialysis patients: cinacalcet is coming to Japan.
Topics: Calcinosis; Calcium; Chelating Agents; Cinacalcet; Coronary Artery Disease; Ethanol; Humans; Hyperpa | 2008 |
3 trials available for niacinamide and Kidney Failure, Chronic
| Article | Year |
|---|---|
Efficacy and safety of nicotinamide in the management of hyperphosphatemia in pediatric patients on regular hemodialysis.
Topics: Adolescent; Chelating Agents; Child; Female; Follow-Up Studies; Humans; Hyperphosphatemia; Kidney Fa | 2016 |
Oral nicotinamide reduces serum phosphorus, increases HDL, and induces thrombocytopenia in hemodialysis patients: a double-blind randomized clinical trial.
Topics: Administration, Oral; Adult; Aged; Diarrhea; Double-Blind Method; Female; Humans; Hyperglycemia; Hyp | 2011 |
Nicotinamide suppresses hyperphosphatemia in hemodialysis patients.
Topics: Aged; Calcium; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle | 2004 |
17 other studies available for niacinamide and Kidney Failure, Chronic
| Article | Year |
|---|---|
18F-PSMA-1007 PET/CT for Initial Staging of Renal Cell Carcinoma in an End-Stage Renal Disease Patient.
Topics: Carcinoma, Renal Cell; Female; Fluorine Radioisotopes; Humans; Kidney Failure, Chronic; Kidney Neopl | 2021 |
Effect of Sevelamer and Nicotinamide on Albumin Carbamylation in Patients with End-Stage Kidney Disease.
Topics: Humans; Kidney Failure, Chronic; Niacinamide; Protein Carbamylation; Serum Albumin; Sevelamer | 2021 |
Outcomes of patients with metastatic renal cell carcinoma and end-stage renal disease receiving dialysis and targeted therapies: a single institution experience.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female; Human | 2014 |
Successful sorafenib treatment for metastatic renal cell carcinoma in a case with chronic renal failure.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Failure, Chron | 2009 |
Clinical results and pharmacokinetics of sorafenib in chronic hemodialysis patients with metastatic renal cell carcinoma in a single center.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Drug A | 2011 |
A new rapid and sensitive LC-MS assay for the determination of sorafenib in plasma: application to a patient undergoing hemodialysis.
Topics: Antineoplastic Agents; Benzenesulfonates; Calibration; Carcinoma, Hepatocellular; Chromatography, Hi | 2011 |
Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Contraindications; Female; Humans | 2012 |
Nicotinamide prevents the development of hyperphosphataemia by suppressing intestinal sodium-dependent phosphate transporter in rats with adenine-induced renal failure.
Topics: Adenine; Animals; Disease Models, Animal; Disease Progression; Intestinal Mucosa; Intestines; Kidney | 2005 |
Thrombocytopenia induced by nicotinamide in hemodialysis patients.
Topics: Humans; Kidney Failure, Chronic; Niacinamide; Phosphorus; Renal Dialysis; Thrombocytopenia; Vitamin | 2005 |
Accumulation of poly(ADP-ribose) polymerase inhibitors in children with chronic renal failure.
Topics: Adolescent; Child; Child, Preschool; Female; Humans; Kidney Failure, Chronic; Male; NAD; Niacinamide | 2006 |
A novel nucleotide found in human erythrocytes, 4-pyridone-3-carboxamide-1-beta-D-ribonucleoside triphosphate.
Topics: Adenosine Kinase; Adenosine Triphosphate; Case-Control Studies; Chromatography, High Pressure Liquid | 2006 |
Relationship between uremic toxins and oxidative stress in patients with chronic renal failure.
Topics: Adult; Aged; Biomarkers; Creatinine; Female; Glutathione; Humans; Kidney Failure, Chronic; Lipid Per | 2007 |
Suppression of tubular anion transport by an inhibitor of serum protein binding in uremia.
Topics: Animals; Biological Transport; Blood Proteins; Humans; Kidney Failure, Chronic; Kidney Tubules; Niac | 1981 |
Accumulation of plasma N-methyl-2-pyridone-5-carboxamide in patients with chronic renal failure.
Topics: Adult; Aged; Aged, 80 and over; Creatinine; Female; Humans; Kidney Failure, Chronic; Kidney Transpla | 2002 |
A comparison of N-1-methylnicotinamide clearance with 5 other markers of renal function in models of acute and chronic renal failure.
Topics: Acetylglucosaminidase; Acute Kidney Injury; Animals; Biomarkers; Kidney Failure, Chronic; Kidney Tub | 1990 |
Estimation of the renal clearance of drugs using endogenous N-1-methylnicotinamide.
Topics: Acute Kidney Injury; Animals; Cephalexin; Cimetidine; Glomerular Filtration Rate; Inulin; Kidney; Ki | 1990 |
Uremic neuropathy. Monitoring of transketolase activity inhibition in a child.
Topics: Brain; Child; Electromyography; Female; Humans; Kidney Failure, Chronic; Leg; Nervous System Disease | 1973 |